Premium
The glial marker YKL‐40 is decreased in synucleinopathies
Author(s) -
Olsson Bob,
Constantinescu Radu,
Holmberg Björn,
Andreasen Niels,
Blennow Kaj,
Zetterberg Henrik
Publication year - 2013
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.25589
Subject(s) - synucleinopathies , cerebrospinal fluid , progressive supranuclear palsy , atrophy , pathology , corticobasal degeneration , medicine , neuroinflammation , parkinson's disease , dementia with lewy bodies , dementia , disease , alpha synuclein
Background Microglia are resident immunosurveillant cells in the central nervous system, and astrocytes are important for blood flow, plasticity, and neurotransmitter regulation. The aim of this study was to investigate whether astrocyte and microglial activation, estimated through markers in cerebrospinal fluid and serum, differed between synucleinopathies, tauopathies, and controls. Methods We analyzed the glial activation markers YKL‐40 and soluble CD14 in serum and cerebrospinal fluid from 37 controls, 50 patients with Parkinson's disease (PD), and 79 P+ patients (those with progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy). Results Cerebrospinal fluid levels of YKL‐40 were decreased significantly in patients who had PD compared with controls ( P < 0.05), patients who had multiple system atrophy ( P < 0.01), and patients who had tauopathies ( P < 0.0001). In addition, cerebrospinal fluid levels of YKL‐40 were significantly lower in patients who had synucleinopathies than in those who had tauopathies ( P < 0.0001). Conclusions The decreased cerebrospinal fluid levels of YKL‐40 suggest that glial activation is reduced in the brains of patients who have Parkinson's disease and synucleinopathies compared with patients who have tauopathies and controls. © 2013 InternationalParkinson and Movement Disorder Society